The Food and Drug Administration Sept. 26 finalized guidance updating the cybersecurity information device makers should submit to its Center for Devices and Radiological Health or Center for Biologics Evaluation and Research for premarket review of devices that have cybersecurity considerations. The recommendations are intended to help manufacturers meet their obligations under section 524B of the Federal Food, Drug, and Cosmetic Act, enacted in December 2022 as part of the Consolidated Appropriations Act of 2023, which defines “cyber device” as one that includes a device or software that can connect to the internet and be vulnerable to cybersecurity threats.

Related News Articles

Headline
In part one of a new blog, John Riggi, AHA national advisor for cybersecurity and risk, and Scott Gee, AHA deputy national advisor for cybersecurity and risk,…
Perspective
Public
This week, the FBI issued an urgent warning to all users — including hospitals — of a critical security soft spot within Oracle’s E-Business Suite, stating “…
Headline
The Health Sector Coordinating Council Oct. 7 released its Sector Mapping and Risk Toolkit, created to help health care providers and other organizations…
AHA Cyber Intel
As of Oct. 3, 2025, 364 hacking incidents had been reported to the U.S. Department of Health and Human Services Office for Civil Rights, affecting over 33…
Headline
The AHA Oct. 6 released a Cybersecurity Advisory urging immediate action against a critical Oracle E-Business Suite vulnerability that is remotely exploitable…
Headline
The AHA has launched an enhanced Cybersecurity and Risk webpage designed to help health care organizations strengthen their defenses against emerging cyber and…